Annals of Oncology Review Time

The official guide is more helpful than many authors realize. It says three things that matter for timing:

• papers of insufficient priority are returned within 3 weeks whenever possible
• authors are normally notified of acceptance, rejection, or revision within 6 weeks
• the journal publishes findings of particular significance in clinical oncology and clinically oriented cancer research (based on SciRev reports and publisher guidelines).

That means the review-time question is tightly tied to the priority question. If the study is not broad or decisive enough, the journal tries to tell you quickly. If the study is important enough to go out, you should still expect a more demanding path than the six-week headline may suggest because revisions, competing reviewer views, and translational validation can all lengthen the real cycle.

The point is not that every paper receives a polished verdict in exactly six weeks. It is that the journal tries to distinguish fast between work that belongs in the conversation and work that does not.

This journal has one of the clearest editorial filters in oncology. The guide says it publishes findings of particular significance. That is not generic prestige language. It is a sorting rule.

Editors can reject quickly when a manuscript is:

• clinically respectable but not practice-changing
• biomarker-heavy without enough independent validation
• translationally interesting but too narrow for broad oncology relevance
• mature enough for a specialty audience but not for an ESMO flagship

That is why fast rejection here does not mean bad science. It usually means the journal does not think the study clears its priority bar.

The slower Annals papers are usually the ones that survive because they are credible, but not yet obviously decisive.

Those cases often involve:

• strong efficacy data with unresolved maturity questions
• biomarker or resistance claims that need firmer validation
• disagreement about how broadly the findings change treatment decisions
• international applicability questions, especially when care pathways differ across regions
• revision cycles where the clinical story is clear but the translational layer still needs tightening

At this level, review time often tracks decision significance, not editorial congestion.

For year-over-year citation data, see the Annals of Oncology citation metrics page.

Annals of Oncology is up from 56.4 in 2023 to 65.4 in 2024, and up dramatically from 14.2 in 2017 to 65.4 in 2024. The 46.8 five-year JIF shows the citation strength is not only short-cycle trial hype. For authors, this usually means the journal has even less reason to blur its triage logic. Demand is strong enough that speed and selectivity can coexist.

The official timing language hides some real variation:

• a fast return for insufficient priority shortens the apparent cycle
• borderline papers can take longer because editors are deciding whether the clinical consequence is broad enough
• a revision request can still be expensive in time if the translational layer is underbuilt
• high-profile trial and biomarker papers often trigger heavier reviewer expectations than the headline timing suggests

So the published timing is useful, but it is not a promise that every reviewed paper will feel quick.

In our pre-submission review work, the biggest avoidable timing mistake is assuming the clinical priority case can live mainly in the cover letter. At Annals of Oncology, the title, abstract, and first results have to make that case early. If the paper only becomes important after a long explanation, the editor often decides it is not an Annals paper before reviewers ever see it.

The manuscripts that move more cleanly are usually the ones where the practice consequence is obvious on page one and the translational work is clearly in service of that consequence.

In our pre-submission review work on Annals of Oncology-targeted manuscripts, three patterns most consistently predict slow review at Annals of Oncology (ESMO). Of manuscripts we screened in 2025 targeting Annals of Oncology and peer venues, the patterns below are the same ones our reviewers flag in real time. The named editorial-culture quirk: Annals of Oncology editors enforce practice-changing threshold with European-oncology clinical-practice relevance; preclinical-only papers without clinical-translation pathway get desk-rejected.

Scope-fit ambiguity in the abstract. Annals of Oncology editors move fastest on manuscripts whose contribution is obviously aligned with the journal's editorial scope (oncology research with practice-changing implications for European-clinical-oncology practice). The named failure pattern: preclinical-only oncology papers without clinical-translation pathway get desk-rejected within 7-10 days. Check whether your abstract reads to Annals of Oncology's scope →

Methods package incomplete for the journal's reviewer pool. Annals of Oncology reviewers expect specific methodological detail. Trials missing pre-specified european-practice-relevance framing extend revision. Check if your methods package is reviewer-complete →

Reference-list and clean-citation failure mode. Editorial team at Annals of Oncology (ESMO) screens reference lists for retracted-paper inclusion. Check whether your reference list is clean against Crossref + Retraction Watch →

Editorial detail (for desk-screen calibration). Verify the current Editor-in-Chief and handling-editor list on the journal's editorial-team page before quoting any name in a submission cover letter. Submission portal: https://www.editorialmanager.com/annonc/. Manuscript constraints: 350-word abstract limit and 4,500-word main-text cap (Annals of Oncology enforces during desk-screen). We reviewed each of these constraints against current journal author guidelines (accessed 2026-05-08); evidence basis for the patterns above includes both publicly documented author-guidelines and our internal anonymized submission corpus.

Manusights submission-corpus signal for Annals of Oncology (ESMO). Of the manuscripts our team screened before submission to Annals of Oncology and peer venues in 2025, the editorial-culture mismatch most consistent across the cohort is Annals Of Oncology editors enforce practice-changing threshold with european-oncology clinical-practice relevance; preclinical-only papers without clinical-translation pathway get desk-rejected. In our analysis of anonymized Annals of Oncology-targeted submissions, the documented review timeline shows a bimodal distribution between manuscripts that clear Annals of Oncology's scope-fit threshold within the first week and those that get extended editorial-board consultation. Top-line triage is handled by the journal's editorial team; verify the current handling editor on the journal's editorial-team page before quoting any name in a cover letter.

For Annals of Oncology, review time is a secondary variable. The primary variable is whether the paper is genuinely priority oncology.

That is why the better next reads are:

• Annals of Oncology journal profile
• Annals of Oncology submission guide
• Annals of Oncology citation metrics
• Annals of Oncology vs. Journal of Clinical Oncology

A Annals of Oncology clinical-priority check is usually more useful than trying to optimize around one timing estimate.

Annals of Oncology review time is best understood as a priority filter. If the manuscript is not competitive for this audience, the journal often tries to say so within three weeks. If the manuscript is competitive, the first outcome can still come fairly quickly, but the harder question becomes whether the study is mature and broad enough to survive top-tier oncology scrutiny. That is the real timeline.

The Manusights Annals of Oncology readiness scan. This guide tells you what Annals of Oncology (ESMO)'s editors look for in the first 1-2 weeks of triage. The review tells you whether YOUR paper passes that check before you submit. We have reviewed manuscripts targeting Annals of Oncology (ESMO) and peer venues; the named patterns below are the same ones the journal's handling editors and outside reviewers flag at the desk-screen and first-review stages. documented review timeline of approximately 7-10 days for desk-screen. 60-day money-back guarantee. We do not train AI on your manuscript and delete it within 24 hours.